Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOAST IT: HIPEC with Doxorubicin and Cisplatin in Pediatric Tumors
NCT04213794Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2019
- Primary completion
- Mar 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cisplatin micelle injection (HA132) and pegylated liposomal doxorubicin in Abdominal neoplasm, Pelvic neoplasm, colon carcinoma and 10 more, sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) up to 6 months. Started Nov 2019; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)pegylated liposomal doxorubicin
03
Conditions
Abdominal neoplasmPelvic neoplasmcolon carcinomadesmoplastic small round cell tumor (DSRCT)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT04213794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213794.